TICKERNERD
Menu
GUTSGUTSHealthcare · Biotechnology

GUTS Stock Forecast: Fractyl Health, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.78
+13.36% on the day

The 7 Wall Street analysts covering Fractyl Health, Inc. hold a median 12-month price target of $5.1 — +556.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$124.2M
Ticker Nerd rank
30 / 100
Median analyst target
$5.10
Analysts covering
7
Total return, dividends reinvested
1W
+14.2%
1M
+0.7%
YTD
−64.7%
1Y
−21.6%
From 52W high
−67.2%
From 52W low
+97.6%
$0.39
$2.37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GUTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fractyl Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
75
Size
73
Revisions
65
Growth
63
Issuance
39
Momentum
16
Value
14
Volatility
14
Quality
7

Accruals (75): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (7): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GUTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GUTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26GUTSHigh $8.00Median $5.10Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $2.00Median $5.10High $8.00

The green dot is the last close — the median target sits +556.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 July 2026Craig-HallumInitiatesBuy$4.00
4 June 2026HC Wainwright & Co.ReiteratesBuy—
24 Apr 2026HC Wainwright & Co.ReiteratesBuy—
26 Mar 2026Canaccord GenuityMaintainsBuy—
30 Jan 2026Morgan StanleyDowngradeEqual-Weight—
2 Dec 2025HC Wainwright & Co.ReiteratesBuy—
21 Nov 2025Canaccord GenuityMaintainsBuy—
26 Sept 2025HC Wainwright & Co.MaintainsBuy—
15 Sept 2025HC Wainwright & Co.InitiatesBuy—
28 Aug 2025Ladenburg ThalmannInitiatesBuy—
14 Aug 2025Canaccord GenuityMaintainsBuy—
15 Apr 2025Canaccord GenuityInitiatesBuy—
3 Feb 2025Morgan StanleyMaintainsOverweight—
28 Feb 2024Evercore ISI GroupInitiatesOutperform—
27 Feb 2024Morgan StanleyInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GUTS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GUTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Fractyl Health, Inc. (GUTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
5.8×

Cheaper than 22% of US stocks

EV / EBITDA
−1.6×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1490.3%

Higher than 1% of US stocks

Return on assets
−74.6%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GUTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GUTSFractyl Health, Inc.$124.2M
30
ANIXAnixa Biosciences, Inc.$124.4M
85
VANIVivani Medical, Inc.$124.5M
40
INOInovio Pharmaceuticals, Inc.$121.9M
44
GNLXGenelux Corp.$121.6M
19
HURATuHURA Biosciences, Inc.$121.4M
17
NAUTNautilus Biotechnology, Inc.$121.3M
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fractyl Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GUTS news & analysis

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

GlobeNewsWire · 20 Aug 2026positive

Fractyl Health announced it will host a virtual Commercial Strategy Day on September 1, 2026 at 11:00 AM ET to discuss the potential commercial opportunity and go-to-market strategy for its Revita® procedural therapy for post-GLP-1 weight maintenance. The company is a clinical stage metabolic therapeutics company focused on obesity and type 2 diabetes.

Why it matters — This event will provide GUTS watchers with insight into Fractyl's potential commercialization path and go-to-market strategy for Revita®, a key pipeline candidate.

Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial

MarketBeat · 14 Aug 2026positive

Fractyl Health (NASDAQ: GUTS) is advancing two one-time treatment approaches intended to provide durable benefits for obesity, type 2 diabetes, and related metabolic diseases, according to CEO Harith Rajagopalan during a Canaccord discussion. The company is eyeing Q4 Revita data and launching a Rejuva gene therapy trial.

Why it matters — A GUTS watcher would care because the company is progressing its two pipeline programs toward key catalysts, including upcoming Q4 data and a new gene therapy trial launch.

Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Fractyl Health, Inc. (GUTS) released its Q2 2026 earnings call transcript, as published by Seeking Alpha. The transcript documents the company's second-quarter 2026 financial results and management discussion.

Why it matters — GUTS watchers would look to this transcript for detail on the company's latest quarterly performance and management commentary.

Fractyl Health Q2 Earnings Call Highlights

MarketBeat · 10 Aug 2026positive

Fractyl Health reported that its Revita endoscopic procedure produced durable weight-maintenance results one year after patients discontinued GLP-1 therapy. The company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and to pursue a potential FDA De Novo submission later that year.

Why it matters — A GUTS watcher would be interested because the reported durability of Revita's weight-maintenance results and the reaffirmed pivotal data and FDA submission timeline bear directly on the company's clinical and regulatory progress.

Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026

GlobeNewsWire · 3 Aug 2026neutral

Fractyl Health, Inc. (Nasdaq: GUTS) announced that it will report its financial results for the second quarter of 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET. The announcement was made on August 3, 2026.

Why it matters — GUTS watchers can expect the upcoming quarterly report to include the company's second quarter financial results and business updates.

FAQ

Frequently asked questions about GUTS stock

What is the GUTS stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Fractyl Health, Inc. have a median 12-month price target of $5.1, with estimates ranging from $2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GUTS stock a buy right now?

Of the 7 analysts covering Fractyl Health, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fractyl Health, Inc. 30 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GUTS?

As at 22 Aug 2026, Fractyl Health, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (75 of 100).

Will GUTS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +556.7% from the last close, and Ticker Nerd's factor model ranks Fractyl Health, Inc. 30 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GUTS stock forecast for 2030?

No analyst covering Fractyl Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GUTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8 over the next 12 months.

How has GUTS stock performed over the past year?

Fractyl Health, Inc. returned -21.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fractyl Health, Inc. do?

Fractyl Health Inc. is a biotechnology company focused on developing advanced treatments for chronic metabolic and inflammatory diseases.

What is the latest news on GUTS?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance". Fractyl Health announced it will host a virtual Commercial Strategy Day on September 1, 2026 at 11:00 AM ET to discuss the potential commercial opportunity and go-to-market strategy for its Revita® procedural therapy for post-GLP-1 weight maintenance. The company is a clinical stage metabolic therapeutics company focused on obesity and type 2 diabetes.

Company

About Fractyl Health, Inc.

Fractyl Health Inc. is a biotechnology company focused on developing advanced treatments for chronic metabolic and inflammatory diseases. The company's primary endeavor is to transform the treatment landscape of type 2 diabetes and related metabolic disorders by targeting the underlying causes rather than merely managing symptoms. Fractyl Health Inc. employs innovative procedural therapies designed to modify the anatomy and functioning of the gastrointestinal tract, potentially altering the disease course. The company's pioneering work significantly impacts the healthcare sector, particularly within gastrointestinal treatment and metabolic disease management arenas. This places Fractyl Health Inc. at the forefront of efforts to address the global epidemic of metabolic diseases, offering new therapeutic options that aim to improve patient outcomes while reducing long-term healthcare costs. Established with a vision to revolutionize metabolic disease treatment, Fractyl Health Inc. is involved in extensive research and clinical trials, underscoring its commitment to delivering breakthrough medical advancements.

CEO Dr. Harith Rajagopalan M.D., Ph.D. · 100 employees · United States · https://fractyl.com